NASDAQ:SNDX

Syndax Pharmaceuticals Competitors

$22.16
-0.63 (-2.76 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.96
Now: $22.16
$22.99
50-Day Range
$20.96
MA: $23.44
$25.18
52-Week Range
$9.83
Now: $22.16
$27.85
Volume449,416 shs
Average Volume672,291 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) Vs. HCM, EBS, ARNA, TPTX, LEGN, and IMAB

Should you be buying SNDX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Syndax Pharmaceuticals, including Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), Arena Pharmaceuticals (ARNA), Turning Point Therapeutics (TPTX), Legend Biotech (LEGN), and I-Mab (IMAB).

Syndax Pharmaceuticals (NASDAQ:SNDX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Hutchison China MediTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Hutchison China MediTech$204.89 million20.77$-106,020,000.00($0.80)-36.55

Syndax Pharmaceuticals has higher earnings, but lower revenue than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Hutchison China MediTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Hutchison China MediTech00203.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Hutchison China MediTech has a consensus target price of $40.00, suggesting a potential upside of 36.80%. Given Hutchison China MediTech's stronger consensus rating and higher probable upside, analysts clearly believe Hutchison China MediTech is more favorable than Syndax Pharmaceuticals.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Hutchison China MediTechN/AN/AN/A

Syndax Pharmaceuticals (NASDAQ:SNDX) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Emergent BioSolutions' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Emergent BioSolutions$1.11 billion3.73$54.50 million$2.9126.58

Emergent BioSolutions has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Emergent BioSolutions02502.71

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Emergent BioSolutions has a consensus target price of $109.8333, suggesting a potential upside of 42.00%. Given Emergent BioSolutions' higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than Syndax Pharmaceuticals.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Emergent BioSolutions12.50%26.68%12.70%

Summary

Emergent BioSolutions beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Arena Pharmaceuticals$806.43 million4.96$397.55 million$7.698.62

Arena Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Arena Pharmaceuticals001503.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Arena Pharmaceuticals has a consensus target price of $91.80, suggesting a potential upside of 38.48%. Given Arena Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arena Pharmaceuticals is more favorable than Syndax Pharmaceuticals.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Arena PharmaceuticalsN/A-33.17%-30.41%

Summary

Arena Pharmaceuticals beats Syndax Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Turning Point TherapeuticsN/AN/A$-72,130,000.00($2.99)-26.40

Syndax Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Turning Point Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Turning Point Therapeutics00703.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 94.70%. Given Turning Point Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turning Point Therapeutics is more favorable than Syndax Pharmaceuticals.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Turning Point TherapeuticsN/A-23.81%-23.08%

Summary

Syndax Pharmaceuticals beats Turning Point Therapeutics on 7 of the 13 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and Legend Biotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
Legend Biotech$64.39 million58.33$-132,970,000.00N/AN/A

Syndax Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Legend Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
Legend Biotech00303.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Syndax Pharmaceuticals.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.9% of Legend Biotech shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Legend Biotech-543.73%-205.60%-43.03%

Summary

Syndax Pharmaceuticals beats Legend Biotech on 6 of the 11 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Syndax Pharmaceuticals and I-Mab's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million703.23$-56,050,000.00($1.84)-12.04
I-Mab$4.31 million862.20$-208,560,000.00($28.90)-1.79

Syndax Pharmaceuticals has higher earnings, but lower revenue than I-Mab. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Syndax Pharmaceuticals and I-Mab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals02902.82
I-Mab00403.00

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. I-Mab has a consensus target price of $70.00, suggesting a potential upside of 35.53%. Given I-Mab's stronger consensus rating and higher probable upside, analysts clearly believe I-Mab is more favorable than Syndax Pharmaceuticals.

Insider and Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.6% of I-Mab shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Syndax Pharmaceuticals and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
I-MabN/AN/AN/A

Summary

I-Mab beats Syndax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.


Syndax Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.